Key result
Intravenous glycoprotein IIb/IIIa receptor inhibitors are superior to placebo in managing non-ST elevation acute myocardial infarction, whereas oral formulations are ineffective for long-term use.
Why the study?
Do glycoprotein IIb/IIIa receptor antagonists reduce ischemic complications in patients with acute coronary syndrome or undergoing percutaneous coronary intervention?
Population
Patients undergoing percutaneous coronary intervention or with non-ST segment elevation acute coronary…
Comparison
Glycoprotein IIb/IIIa receptor antagonists vs Placebo or traditional regimens
Design
Review
Authors
Loading...
Supports IV GP IIb/IIIa in NSTEMI but cautions against oral long-term use; leaves open validation in contemporary ACS regimens.
Do glycoprotein IIb/IIIa receptor antagonists reduce ischemic complications in patients with acute coronary syndrome or undergoing percutaneous coronary intervention?
Intravenous glycoprotein IIb/IIIa receptor antagonists are effective in reducing ischemic events in non-ST elevation acute myocardial infarction, while oral formulations lack long-term efficacy.
Gowda et al. (2004) conducted a review in Acute coronary syndrome. Glycoprotein IIb/IIIa receptor antagonists vs. Placebo was evaluated. Intravenous glycoprotein IIb/IIIa receptor inhibitors are superior to placebo in managing non-ST elevation acute myocardial infarction, whereas oral formulations are ineffective for long-term use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: